The landscape of multiple sclerosis (MS) treatment has substantially evolved over the past few years, and it is now agreed that starting treatment early generally provides the best chance at slowing the progression of MS. Eva Kubala Havrdová, MD, PhD, General University Hospital, Charles University, Prague, Czechia, shares insights into the optimal choice of disease-modifying therapy (DMT) in an individual patient. Before starting a high-efficacy treatment, the patient’s prognostic factors and comorbidities should be considered. Clinicians should also discuss the treatment decisions with the patient to ensure that they are supported to make decisions that are right for them. Currently, precision medicine is not available in the MS space. Still, a personalized approach should be taken, where a patient is closely monitored throughout treatment, and if the therapy is ineffective in controlling the disease, it should be switched. When switching therapies, safety concerns need to be considered, but the patient’s well-being and effective disease control remain the most critical aspects. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.